Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))

5. oktober 2026 oppdatert av: Duke University

RECOVER-ENERGIZE: En plattformprotokoll for evaluering av intervensjoner for treningsintoleranse ved postakutte følgetilstander av SARS-CoV-2-infeksjon (PASC)

This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.

This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC).

The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.

Studieoversikt

Detaljert beskrivelse

Study interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix. Study intervention appendices may be added or removed according to adaptive design and/or emerging evidence.

The platform protocol enrolls participants who meet study eligibility criteria. After completing initial screening assessments, eligible participants are assigned to one of the study intervention appendices that are actively enrolling. Participants must meet certain criteria within a specific appendix in order to be included in that appendix. Once assigned to an appendix, eligible participants are randomized to either the study intervention group or a control group.

Studietype

Intervensjonell

Registrering (Faktiske)

300

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • All sites listed under NCT06404047

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

• See NCT06404047 for RECOVER-ENERGIZE: Platform Protocol level inclusion and exclusion criteria which applies to this appendix

Additional Appendix B (Structured Pacing (PEM)) Level Inclusion Criteria:

  1. Participant identifies new PEM following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent
  2. Score of 2 or greater for both frequency and severity for any of the first 5 questions on the Screening mDSQ-PEM AND Answer of YES to either item 7 or 8 on Screening mDSQ-PEM, and response of >14 h in item 9.

or Score of 3 or greater on any severity question(regardless) and answer of YES to either item 7 or 8 on the Screening mDSQ-PEM, and response of >14h in item 9.

Additional Appendix B (Structured Pacing (PEM)) Level Exclusion Criteria:

  1. Inability to attend in-person screening visit or participate in weekly visits (in-person [≥ 1] and remote)
  2. Participant was previously enrolled in Appendix A of this protocol and has NOT completed the full study follow-up period of Appendix A

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Structured Pacing (PEM)

Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.

Participants in this group will complete weekly pacing sessions for 12 weeks. Pacing sessions will last about 30 minutes, as tolerated. Each participant will meet with a provider 'pacing coach' who has received study-specific education about PEM and how to create and manage pacing strategies for participants. Sessions include PEM symptom and trigger assessment; task, function and activity analysis; adaptations and modifications.

Annen: Usual Care

Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.

Participants in this group will receive basic education about PEM with a weekly call by site study staff for support and communication.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Frequency of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
Tidsramme: Baseline, week 12 (End Of Intervention, EOI)

Symptom frequency is rated on a 5-point Likert scale: 0 = none of the time, 1 = a little of the time, 2 = about half the time, 3 = most of the time, and 4 = all of the time.

Baseline, week 12 (End Of Intervention, EOI)
Change in Severity of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
Tidsramme: Baseline, week 12 (EOI)

Symptom severity is rated on a 5-point Likert scale: 0 = symptom not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.

Baseline, week 12 (EOI)
Change in Duration of PEM Symptoms, as Measured by the Modified DePaul Symptom - Post-Exertional Malaise Questionnaire (mDSQ-PEM)
Tidsramme: Baseline, week 12 (EOI)

Ordinal categorical response: <=1 hour, 2-3 hours, 4-10 hours, 11-13 hours, 14-23 hours, >=24 hours. Reported as the number of participants who provided each response.

Baseline, week 12 (EOI)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in PASC Symptoms, as Measured by the PROMIS-Cog Questionnaire
Tidsramme: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

The PROMIS Short Form v.2.0 - Cognitive Function 8a (PROMIS-Cog) is the PROMIS Short Form to assess cognitive function and is a self-report, 8-item questionnaire targeting cognitive function in the past seven days. T-Scores in a healthy reference population have mean=50 and standard deviation = 10, with higher scores indicating higher functioning.

Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Quality of Life, as Measured by the PROMIS-29+2
Tidsramme: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

The PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health).

Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Quality of Life, as Measured by the EQ-5D 5L
Tidsramme: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

The EQ-5D is a standardized measure of health status. Mobility was measured on a scale from 1 (no problems in walking) to 5 (unable to walk).

Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Step Count (Physical Activity) as Measured by Actigraphy
Tidsramme: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

Actigraphy will be measured by Fitbit. Participant steps were considered valid from days where they wore the Fitbit at least 10 waking hours. Average steps were calculated from subjects with at least 5 consecutive days of valid data within a week window of their expected visit dates.

Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Physical Activity, as Measured by the PROMIS SF-Physical Function (PROMIS-PF)
Tidsramme: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

The PROMIS Short Form v2.0 - Physical Function 8b (PROMIS-PF) consists of 8 items. The PROMIS Physical Function instruments measure self-reported capability rather than actual performance of physical activities. T-Scores in a healthy reference population have mean = 50 and standard deviation = 10, with higher scores indicating higher functioning.

Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)
Change in Orthostatic Hypotension, as Measured by the Modified Orthostatic Hypotension Questionnaire (mOHQ)
Tidsramme: Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

The Orthostatic Hypotension Questionnaire (OHQ) is a measure of orthostatic intolerance. The modified OHQ (mOHQ) measure used in this study includes a total of ten items related to daily activities and symptoms. The OHQ composite score ranges from 0 (no burden) to 10 (maximal burden). Higher scores are worse. The OHQ composite score includes 6 symptom items (OISA) and 4 daily activity items (OIDAS).

Screening, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in PASC Symptoms, as Measured by the PASC Symptom Questionnaire
Tidsramme: Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

The PASC Symptom Questionnaire is a 33-question survey for self-reporting multiple PASC-related symptoms across multiple systems.

Baseline, week 6 (Middle of Intervention), week 12 (EOI), month 6 (EOS)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studiestol: Gary M Felker, MD, Duke Clinical Research Institute
  • Studiestol: Barry Make, MD, National Jewish Health
  • Studiestol: Lucinda Bateman, MD, Bateman Horne Center
  • Studiestol: Janna Friedly, MD, MPH, University of Washington

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juli 2024

Primær fullføring (Faktiske)

18. august 2025

Studiet fullført (Faktiske)

17. november 2025

Datoer for studieregistrering

Først innsendt

3. mai 2024

Først innsendt som oppfylte QC-kriteriene

6. mai 2024

Først lagt ut (Faktiske)

8. mai 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

The summary of the results will be shared on the study website: https://recovercovid.org/

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere